Context: The Maharashtra Cabinet, chaired by Chief Minister Devendra Fadnavis, has officially approved the establishment of a ₹300-crore High-Energy Medical Cyclotron Project (HEMCP) in Nagpur.
About The High-Energy Medical Cyclotron Project (HEMCP):
What It Is?
- The High-Energy Medical Cyclotron Project (HEMCP) is a state-of-the-art nuclear medicine facility centered around a high-energy particle accelerator. The project is designed to manufacture specialized, short-lived medical radioisotopes locally, which are indispensable for advanced oncological imaging, targeted cancer therapies, and molecular research.
How It Works?
- Particle Acceleration: The cyclotron uses a combination of strong magnetic and alternating radio-frequency electric fields to accelerate charged subatomic particles (such as protons or deuterons) along a rapidly expanding spiral path inside a vacuum chamber.
- Target Bombardment: Once these particles reach extremely high kinetic energy levels, they are directed out of the spiral track as a focused beam to bombard a stable target material (like specific isotopes of oxygen, nitrogen, or liquid metals).
- Nuclear Transformation: The high-energy collision alters the atomic nuclei of the target material, transforming stable atoms into short-lived, unstable radioactive isotopes (such as Fluorine-18, Carbon-11, or Iodine-123).
- Radiopharmaceutical Synthesis: These newly created raw radioisotopes are immediately transferred to automated lead-shielded hot cells. Inside, they are chemically bonded with biological molecules (like glucose) to synthesize medical-grade radiopharmaceuticals that patients can safely ingest or receive intravenously for diagnostic scanning.
Key Features of the Nagpur HEMCP:
- Strategic Multi-State Catchment Area: Located centrally, the facility will provide advanced cancer-care support to patients across five states within a 500-km service radius.
- Institutional Network Integration: It will supply critical radiopharmaceuticals to AIIMS Nagpur, NCI, and GMC, strengthening regional cancer-treatment capacity.
- 50:50 Financial Architecture: The ₹300-crore project is jointly funded by the Medical Education and Industry Departments, with 30 hectares already allotted.
- Specialized Corporate Governance: A dedicated SPV under Mahacare will manage operations, ensuring professional oversight and coordinated implementation.
Major Medical Applications:
- Advanced PET-CT Diagnostic Imaging: Produces radioisotopes such as Fluorine-18 for PET-CT scans, enabling early and accurate detection of cancerous cells.
- Targeted Nuclear Medicine Therapies: Facilitates creation of radiopharmaceuticals that deliver focused radiation directly to tumors while minimizing collateral damage.
- Oncological Research and Drug Discovery: Acts as a research hub supporting clinical trials and development of new imaging tracers and cancer therapies.
- Precision Personal Dose Calibration: Local production ensures short-lived isotopes reach hospitals quickly, enabling accurate patient-specific diagnostic dosing.
